Medindia LOGIN REGISTER
Medindia
Advertisement

Targeted Treatment can Reduce Relapse in Children With Acute Myeloid Leukemia

by Bidita Debnath on December 10, 2013 at 5:12 PM
 Targeted Treatment can Reduce Relapse in Children With Acute Myeloid Leukemia

In pediatric patients with acute myeloid leukemia (AML), the addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival.

Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease.

Advertisement

The study (abstract #355) evaluated a total of 1,022 children averaging 10 years old at trial sites nationwide, led by Alan Gamis, MD, MPH, Associate Division Director, Section of Oncology at Children's Mercy Hospital in Kansas City. It will be highlighted in an oral presentation Monday, Dec. 9, at the American Society of Hematology annual meeting in New Orleans.

"Chemotherapy has limits. Particularly in children, increasing doses further can become too toxic for the patient while still not achieving the desired effect on the cancer," said Dr. Gamis. "This study is significant because it shows for the first time that this targeted treatment can augment the effects of chemotherapy in children and effectively reduce their risk of relapse. We found it was most effective in the patients most at risk."
Advertisement

Gemtuzumab was removed from the U.S. market in 2010 because the U.S. Food and Drug Administration determined the potential risks of the drug outweighed the potential benefits. Recent research with the compound has raised questions about whether that action may have been premature. This data supports recent findings in adults with AML that gemtuzumab reduced their risk of relapse when added to standard chemotherapy.

"This could be an important treatment option for critical patients," said Dr. Gamis. "Gemtuzumab appears to have a real impact in increasing the likelihood of long-term survival in high-risk patients."

In this study, patients were treated with gemtuzumab or a standard treatment regimen. Compared with standard regimens, the addition of gemtuzumab was associated with better disease-free survival (61 vs. 55%) and reduced relapse risk (33 vs. 41%). It did not significantly improve overall survival (74 vs. 70%).

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

AI Shows Promise in Identifying ADHD
The AI method shows promise in identifying imaging biomarkers for diagnosing ADHD.
Life Expectancy Gap for Autistic Individuals Revealed
Diagnosed autistic individuals showed increased premature mortality in the UK, highlighting urgent needs to address associated inequalities.
Exploring How Hearing Impairment Shapes Dementia Risk
Study reveals a correlation between hearing impairment and distinct brain region variances, contributing to dementia.
Coffee and its Role in Neurodegenerative Disorders
Financial impact of caring for individuals with neurodegenerative disorders reaches hundreds of billions annually in the United States.
Healthcare Industry Struggles With Tech Skills Shortage
Experts emphasize that addressing the skills gap demands immediate attention and innovative solutions, including education, re-training, and significant time investment.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Targeted Treatment can Reduce Relapse in Children With Acute Myeloid Leukemia Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests